A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients [PDF]
Scientific Reports, 2017 Exogenous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers. Arginine deiminase (ADI) inhibits growth in various ASS-deficient cancers by depleting arginine. The efficacy of pegylated ADI (ADI-PEG20) in relapsed/
Hui-Jen Tsai +2 more
exaly +4 more sources
Efficacy of Arginine Depletion by ADI-PEG20 in an Intracranial Model of GBM [PDF]
Cell Death and Disease, 2018 Glioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brain ...
Keittisak Suwan, Nabil Hajji, Tim Crook
exaly +4 more sources
Hypoxia-Induced Nitric Oxide Production and Tumour Perfusion Is Inhibited by Pegylated Arginine Deiminase (ADI-PEG20) [PDF]
Scientific Reports, 2016 The hypoxic tumour microenvironment represents an aggressive, therapy-resistant compartment. As arginine is required for specific hypoxia-induced processes, we hypothesised that arginine-deprivation therapy may be useful in targeting hypoxic cancer cells.
Natalie Burrows +2 more
exaly +6 more sources
Decreased Argininosuccinate Synthetase Expression in Thai Patients With Cholangiocarcinoma and the Effects of ADI‑PEG20 Treatment in CCA Cell Lines [PDF]
Oncology Letters, 2018 Cholangiocarcinoma (CCA) is a severe cancer with poor prognosis. The aim of the present study was to explore the expression of argininosuccinate synthetase (ASS), as well as the possibility of using pegylated arginine deiminase (ADI-PEG20) for the ...
Niramol Savaraj +2 more
exaly +3 more sources
The Combination of ADI-PEG20 and TRAIL Effectively Increases Cell Death in Melanoma Cell Lines [PDF]
Biochemical and Biophysical Research Communications, 2010 Current treatment for advanced, metastatic melanoma is not very effective, and new modalities are needed. ADI-PEG20 is a drug that specifically targets ASS-negative malignant melanomas while sparing the ASS-expressing normal cells.
Lynn G Feun +2 more
exaly +3 more sources
Arginine Depletion Therapy With ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type [PDF]
Clinical Cancer Research, 2020 PURPOSE: Many rare ovarian cancer subtypes, such as small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), have poor prognosis due to their aggressive nature and resistance to standard platinum- and taxane-based chemotherapy.
Christine Chow +2 more
exaly +4 more sources
Cancer Medicine, 2021 Introduction We evaluated the arginine‐depleting enzyme pegargiminase (ADI‐PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1‐deficient non‐squamous non‐small cell lung cancer (NSCLC) via a phase 1 dose‐expansion trial with ...
Peter W. Szlosarek +17 more
doaj +2 more sources
The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
Drug Target Insights, 2007 It has been shown that melanoma cells do not express argininosuccinate synthetase (ASS) and therefore are unable to synthesize arginine from citrulline.
Niramol Savaraj +7 more
doaj +3 more sources
Inhibition of Pathological Angiogenesis in Oxygen-Induced Retinopathy by Arginine Depletion With ADI-PEG20 [PDF]
Experimental Eye ResearchSyed A H Zaidi +2 more
exaly +2 more sources
Exploiting Arginine Auxotrophy With Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation [PDF]
Molecular Cancer Therapeutics, 2019 Sunil Krishnan +2 more
exaly +2 more sources